Evidence map›Paper›PMID 40016807›Full record

Trial reportItalian journal of pediatrics2025

Micafungin versus Amphotericin B in treatment of invasive fungal infection in preterm neonates: a randomized control trial.

Mariam John Amin Ibrahim, Marwa Saad Mohammed Fathy, Mertte Ashraf Thabet Ghobrial, Maha Hassan Mohamed

Registry-linked trialAbstract readClinical Trial, Phase IVComparative StudyRandomized Controlled Trial
In one paragraph

Trial report in Italian journal of pediatrics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06413056 (Micafungin Versus Amphotercine B in Treatment of Invasive Fungal Infection In Preterm Neonates), which is not on this map. Cited by 4 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT06413056 phase4completednot on this map

Micafungin Versus Amphotercine B in Treatment of Invasive Fungal Infection In Preterm Neonates: A Randomized Control Trial

TypeinterventionalSponsorAin Shams UniversityRan2022 to 2023Enrolled56ConditionsNeonatal Infection, Invasive Fungal InfectionsArmsMicafungin, Amphotericin B
3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Antifungal therapy for newborn infants with invasive fungal infection.The Cochrane database of systematic reviews · 2026
    Pooled it
  2. Brazilian guidelines for the diagnosis and treatment of candidemia and invasive candidiasis in adults and children.The Brazilian journal of infectious diseases : an official publication of the Brazilian Society of Infectious Diseases
    Guideline
  3. Article
  4. Severe Congenital Candidiasis due toCase reports in pediatrics · 2026
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Mariam John Amin IbrahimPediatrics and Neonatology, Faculty of Medicine, Ain Shams University, Cairo, Egypt. mariam.john@med.asu.edu.eg.ORCID http://orcid.org/0000-0002-4936-8303
Marwa Saad Mohammed FathyProfessor of Medical Microbiology and Immunology, Faculty of Medicine, Ain Shams University, Cairo, Egypt.
Mertte Ashraf Thabet GhobrialEgyptian Ministry of Health and Population, Masr El Hora Hospital, Minia, Egypt.
Maha Hassan MohamedPediatrics and Neonatology, Faculty of Medicine, Ain Shams University, Cairo, Egypt.ORCID http://orcid.org/0000-0001-7353-9857

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundMicafungin, Amphotericin B, and Fluconazole are the primary therapeutic agents employed to address invasive fungal candidiasis in neonates. Resistance to fluconazole is gradually developing in neonatal intensive care units. We aimed to conduct a comparative analysis of Micafungin and Amphotericin B in terms of their effectiveness and safety in the treatment of invasive fungal infections in neonates.

methodsFifty-six preterm neonates with invasive fungal infection proven by fungal culture and who had received fluconazole for at least one week were included in our study and were divided randomly into two groups. Micafungin group: twenty-eight preterms received Micafungin at a dose of 8 mg/kg/day for 14 days. Amphotericin B group: twenty-eight preterms received amphotericin B at a dose of 1 mg /kg/day for 14 days. Clinical and laboratory follow up by fungal culture were performed after 14 days.

resultsNeonates in the Micafungin group showed significant increased percentage for complete cure of the fungal infection compared to Amphotericin B group 18(64.3%) vs. 10(35.7%) respectively and decreased percentage of incomplete cure 10(35.7%) vs. 18(64.3%) respectively with p-value 0.030. A higher percentage of neonates were completely cured for both candida albicans (65.2%) and non-albicans (60%) in the micafungin group. Duration of respiratory and circulatory support was significantly shorter also. No additional drug side effects were observed with Micafungin except for mild hypomagnesemia. There was an increase in blood urea nitrogen with Amphotericin B.

conclusionMicafungin is effective and well tolerated for the treatment of invasive fungal infections in preterm neonates.

trial registrationThe current study was approved by clinicaltrials.org and the protocol ID NCT06413056 was retrospectively registered in on 11th of march 2024. https://clinicaltrials.gov/study/NCT06413056?cond=micafungin%20in%20neonates&rank=2 .

Indexed as

Amphotericin BAntifungal AgentsInfant, Premature, DiseasesInvasive Fungal InfectionsMicafunginFemaleHumansInfant, NewbornInfant, PrematureMaleTreatment OutcomeAmphotericin BAntifungal AgentsMicafunginAmphotericin BCandida non albicansInvasive fungal infectionMicafunginNeonatesPreterm

Identifiers

PMID40016807
PMCPMC11866894

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.